Overview

The Effect of LH-Priming During Early Follicular Phase in IVF Treatment.

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Female
Summary
To evaluate the effect of LH-activity supplementation during the early follicular phase in GnRHa down-regulated women undergoing IVF in terms of S-Estradiol levels on hCG day by comparing different combinations with HP-HMG and r-FSH.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Central Jutland Regional Hospital
Treatments:
Menotropins
Criteria
Inclusion Criteria:

- Females between the ages of 18- 38 years (both included) at the time of randomisation

- Patients for whom treatment with gonadotrophins and GnRH agonist (long protocol) in
IVF setting is considered appropriate according to the criteria of the participating
centre

- Infertility for at least 1 year before randomisation (except for tubal infertility)

- A maximum of two previous consecutive unsuccessful IVF cycles (i.e. not resulting in
an ongoing pregnancy

- 25- 34 days of menstruation cycle

- Body mass index (BMI) < 29 kg/m2

Exclusion Criteria:

- Any clinically significant systemic disease (e.g., insulin dependent diabetes)

- Endocrine or metabolic abnormalities (pituitary, adrenal, thyroid, pancreas, liver, or
kidney) which can compromise participation in the study

- Any concomitant medications that would interfere with evaluation of study medications.
Specifically, any non-study hormonal therapy (except for thyroid medication),
prostaglandin inhibitors (NSAIDs, including aspirin) and psychotropic agents
(phenothiazine's, major tranquillisers) at the time of study entry. Note: these
medications are disallowed for the study duration.

- Presence of clinically significant uterine fibroids

- Undiagnosed vaginal bleeding

- Tumours of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus

- Pregnancy, lactation or contraindication to pregnancy - must be confirmed by negative
urinary pregnancy test at randomisation